Regulatory news
Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy.
![Immagine News](/media/xuhk5yjv/immagine-regulatory-news.png?anchor=center&mode=crop&width=722&height=442)
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resistance in adults, children and adolescents receiving dolutegravir-based ART.
This sentinel method is implemented complementary to WHO-recommended methods for estimating nationally representative levels of acquired HIV drug resistance.
Additional information to the following link: https://www.who.int/publications/i/item/9789240063204
Grazie per il tuo feedback!